Drug intelligence / Profile preview

Pearl-111

Development stage: Preclinical
Lead developer: PearlsInMires
Modality: Small Molecules

Overview

Pearl-111 is a small molecule combination therapy being developed by PearlsInMires for the treatment of gastrointestinal (GI) solid tumors. The drug is designed to target Schlafen 11 (SLFN11) and the ADP-ribose pathway, which are critical components of the cellular DNA damage response. SLFN11 expression is a recognized biomarker that sensitizes cancer cells to DNA-damaging agents, and by co-targeting these pathways, Pearl-111 aims to enhance therapeutic efficacy and overcome resistance in solid tumors. As of 2024, the program is in the IND-enabling stage, with the company projecting the completion of IND-enabling tests by 2026.

Targets

PARP1 (Poly (adp-ribose) polymerase 1)SLFN11 (Schlafen family member 11)

Beyond the preview

Go deeper on Pearl-111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pearl-111.

Explore the full profile